CASE REPORT
Unusual occurrence of hemophagocytic lymphohistiocytosis in HIV-positive person with visceral leishmaniasis
 
More details
Hide details
1
Fattouma Bourguiba Hospital, Tunisia
 
 
Submission date: 2020-06-18
 
 
Final revision date: 2021-03-22
 
 
Acceptance date: 2021-03-23
 
 
Publication date: 2021-12-26
 
 
HIV & AIDS Review 2021;20(4):311-313
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Visceral leishmaniasis is a well-recognized opportunistic infection in people living with HIV (PLHIV). Unlike adults, in children this infection is frequently associated with hemophagocytic lymphohistiocytosis (HLH). We report a case of HLH in HIV-positive person with visceral leishmaniasis.

Case description:
A 25-year-old man known living with HIV since 2013 was admitted to infectious diseases department in March 2017. His clinical examination was clear. His initial viral load was 630,000 copies/mm3 and CD4+ cells count was 12/mm3. No opportunistic infections were noted. The patient was started on antiretroviral therapy. During hospitalization, he developed fever, asthenia, rhinorrhea, and odynophagia. The diagnosis of HLH was retained because of pancytopenia, cytolysis, hyponatremia, high level of ferrinemia, and hemophagocytosis. Etiological investigations revealed positive Leishmania PCR. Also, Leishmania was detected in sternal puncture. Patient received meglumine antimoniate (glucantime) 20 mg/kg/day for 21 days with favorable outcomes. To prevent relapse, he received meglumine antimoniate 20 mg/kg/month as long as his CD4+ count was less than 100 cells/mm3. After 1-year follow up, no relapse was detected.

Conclusions:
Clinical and laboratory presentation of visceral leishmaniasis in PLHIV may differ from classic kala-azar. In our case, HLH was the reason for VL discovery.

 
REFERENCES (13)
1.
Panda PK, Mohta S, Sharma SK, Ray A, Arava S, Vyas S. A case of pseudorheumatism with submasseteric abscess and HLH in a patient with visceral leishmaniasis: a diagnostic dilemma. J Vector.
 
2.
Borne Dis 2016; 53: 387-390.
 
3.
Chen L, Weng H, Li H, et al. Potential killer in the ICU – severe tuberculosis combined with hemophagocytic syndrome. Medicine (Baltimore) 2017; 96: e9142.
 
4.
Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/HIV co-infections in the second decade. Indian J Med Res 2006; 123: 357-388.
 
5.
Alemayehu M, Wubshet M, Mesfin N, Gebayehu A. Prevalence of human immunodeficiency virus and associated factors among visceral leishmaniasis infected patients in northwest Ethiopia:.
 
6.
a facility based cross-sectional study. BMC Infect Dis 2017; 17: 152.
 
7.
WHO. Visceral leishmaniasis. Available at: http://www.who.int/.
 
8.
leishmaniasis/visceral_ leishmaniasis/en/2016.
 
9.
Lins Guedes D, Medeiros Z, da Silva ED, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in Pernambuco, Brazil. Am J Trop Med Hyg 2018; 99: 1541-1546.
 
10.
de Carvalho FHG, Lula JF, de Freitas Teles L, Prates Caldeira A, de Carvalho SFG. Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in an endemic area in the north of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2020; 53: e20190491.
 
11.
World Health Organization Regional Office for Europe. Manual on case management and surveillance of the leishmaniases in the WHO European Region. Denmark: World Health Organization Regional Office for Europe; 2017.
 
12.
Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Visceral leishmaniasis and HIV coinfection in east Africa. PLoS Negl Trop Dis 2014; 8: e2869.
 
13.
Monge-Maillo B, Norman FF, Cruz I, et al. Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis 2014; 8: e3021.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top